Business & Regulation

Changing your company name takes more than putting a new sign on the door.

Can certain buzzwords really sway public perceptions of a new drug?

Round and round she goes, where she stops nobody knows. How will the current merger and acquisition fever affect the industry?

Sitting Down With... John Talley, Chief Scientific Officer at Euclises Pharmaceuticals, St. Louis, USA.

How can the pharma industry capitalize on the growth potential of emerging markets?

Grant Lindman is director of Eli Lilly’s global anticounterfeiting operations and is passionate about fighting fake medicines.

Recently, Tim Mackey and colleagues examined the extent to which counterfeit drugs had penetrated global legitimate supply chains.

The EMA fights to reinstate its former executive director – and the FDA’s new leader is still unconfirmed

Expedited regulatory approvals bring medicines to market faster – but are they the right drugs?

Mislabeled, substandard or falsified medicines are the perfect opportunity for criminals looking for low risks and high rewards.